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Th  e prevailing clinical consensus is that TNF inhibitors 
are both eﬀ   ective and cost-eﬀ   ective in patients with 
established active rheumatoid arthritis (RA) who have 
failed to respond to methotrexate. Th  is consensus is 
challenged by new research from Wolfe and Michaud [1]. 
Th  eir  ﬁ  ndings, although important, are controversial. We 
have placed these ﬁ  ndings into context by outlining the 
cases for and against the current use of TNF inhibitors.
Th  ree strands of evidence support using TNF inhi  bi-
tors. Firstly, the inhibitors reduce joint inﬂ  amma  tion. 
Secondly, TNF inhibitors improve disability measured 
using the health assessment questionnaire (HAQ). 
Th   irdly, HAQ scores do not increase in patients receiving 
TNF inhibitors but continue to increase in patients with 
active RA receiving disease-modifying anti-rheumatic 
drugs (DMARDs). Economic modelling suggests TNF 
inhibitors are cost-eﬀ   ective, and regulators like the 
National Institute for Health and Clinical Excellence have 
approved their use in established active RA [2].
Most evidence for using TNF inhibitors in active 
established RA comes from randomised controlled trials 
(RCTs) in patients in whom methotrexate treatment has 
failed [3,4]. Th   is evidence is supported by observational 
studies from national registers [5-7] of their use in 
routine clinical practice. Th   e depth of evidence makes a 
compelling case for using TNF inhibitors in established 
active RA.
Doubts about the relative beneﬁ  ts of TNF inhibitors 
have surfaced in early RA. A systematic review of RCTs 
in early RA showed that TNF inhibitors with metho-
trexate have similar eﬃ   cacy to DMARD combinations 
[8]. An analysis of economic data suggested they were no 
more eﬀ  ective than optimally used DMARDs [9]. Th  e 
National Institute for Health and Clinical Excellence has 
not recommended their use in early active RA [1]. Th  is 
does not mean that any use of TNF inhibitors in early RA 
is incorrect; only that their general use is unaﬀ  ordable. If 
the selective use of TNF inhibitors and other biologics in 
early RA prevented severe disability developing in patients 
with established disease, it is likely to be good value for 
money.
New data from Wolfe and Michaud [1] question the 
widespread use of TNF inhibitors in established RA. In a 
study of over 18,000 RA patients they found that overall 
HAQ scores increased by 0.5% of maximal each year 
(0.016). Th  e HAQ score did not increase in patients 
receiving TNF inhibitors; prior to biologic treatment, the 
score increased by 1% per year (0.032). For comparison, 
previous studies have reported an annual rate of HAQ 
progression of 1% (0.034) in all patients [10]. Wolfe and 
Michaud con  clude that TNF inhibitors may provide only 
modest incre  mental beneﬁ   ts over best conventional 
therapy as currently used in North America. If they are 
correct, the economic argument underpinning the 
widespread use of TNF inhibitors in established RA is 
unsustainable.
Is it reasonable to think that RCTs and observational 
studies might overestimate the cost-eﬀ  ectiveness of TNF 
inhibitors? RCTs in established RA patients who have 
failed methotrexate compare TNF inhibitors plus metho-
trexate against placebo plus methotrexate. Such RCTs are 
ideal for establishing eﬃ     cacy; however, the control 
groups are unrealistic for modelling cost-eﬀ  ectiveness. In 
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DMARD or would have started DMARD combinations. 
In addition, RCTs enrol highly selected patients with 
active disease and without co-morbidities; in routine 
practice, patients with milder disease or co-morbidities 
are treated and they may respond diﬀ  erently [11].
Observational studies also have signiﬁ  cant limitations. 
Biologics registers are excellent tools for identifying 
adverse events. When examining eﬃ   cacy  and  cost-
eﬀ   ective  ness, control patients become the studies’ 
Achilles heel. Whilst they accurately record the eﬀ  ect of 
TNF inhibitors on HAQ scores, their controls not treated 
with biologics may not be comparable. Historical data are 
potentially misleading because the severity of RA may be 
decreasing over time [12]. Contemporary controls are 
often patients with contraindications to biologics and are 
likely to have atypical outcomes.
None of these limitations means that the interpreta-
tions made by Wolfe and Michaud are necessarily 
correct, and their data have some weaknesses. Th  eir 
patients have a surfeit of mild disease and may not be 
representative of North America as a whole, although 
they included an external validation cohort to minimise 
this concern. Th   e methods they use to collect data may 
selectively lose severe patients during follow up. 
Nevertheless, these authors have raised crucial concerns 
and it is vital their conclusions are examined by other 
groups. Firstly, the authors suggest that the cost-
eﬀ  ectiveness of TNF inhibitors may be overestimated. 
We therefore need to obtain more data for modelling 
HAQ progression in patients on nonbiological 
treatments. Secondly, we need to undertake RCTs that 
compare biologics with best standard treatment, such as 
combination DMARDs. Finally, the current use of 
biologics may be suboptimal and we need to explore 
alternative ways of using them that may be more eﬀ  ective 
and more cost-eﬀ  ective. For example, short courses of 
biologics during ﬂ  ares may be as eﬀ  ective as long-term 
use. Biologics are very expensive treatments and 
specialists must continually explore their limitations as 
well as identifying their beneﬁ  ts.
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